Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.","authors":"Kristine E Mayer, Lydia Warburton, Anne Zaremba, Sarah Preis, Yannick Foerster, Tilo Biedermann, Oana-Diana Persa","doi":"10.1111/jdv.20672","DOIUrl":"https://doi.org/10.1111/jdv.20672","url":null,"abstract":"<p><strong>Background: </strong>Immune-checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established.</p><p><strong>Objectives: </strong>The aim of this systematic review and meta-analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who discontinued therapy due to adverse events.</p><p><strong>Methods: </strong>MEDLINE/PubMed, Embase and the Cochrane Library were searched for studies reporting outcomes after ICI discontinuation in patients with advanced melanoma. Pooled 1- to 3-year progression-free survival (PFS) and overall survival (OS) rates were estimated using random-effects models. The impact of the reason for treatment discontinuation, therapy regime and treatment duration on relapse-free survival was evaluated.</p><p><strong>Results: </strong>Twenty studies including 1832 patients were analysed. The pooled 1- and 3-year PFS rates after therapy stop were 86% (95% CI 80%-91%) and 71% (95% CI 64%-77%). A significantly higher 1-year PFS rate was observed in patients who electively discontinued treatment in contrast to toxicity-related therapy cessation (91% vs. 79%). Longer ICI treatment was associated with a higher PFS rate. 1- and 3-year OS rates post ICI treatment discontinuation were 96% (95% CI 91%-99%) and 86% (95% CI 79%-92%).</p><p><strong>Conclusions: </strong>Most patients remained relapse-free after ICI treatment. Patients with a treatment duration of at least 2 years are ideal candidates for treatment cessation, while treatment discontinuation may be considered after at least 1 year of ICI. PROSPERO number: CRD42024543781.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolic events in patients treated with Janus kinase inhibitors for atopic dermatitis.","authors":"Catherine Droitcourt, Sandrine Kerbrat, Delphine Staumont-Salle, Alain Lescoat, Emmanuel Oger, Lucie-Marie Scailteux","doi":"10.1111/jdv.20682","DOIUrl":"https://doi.org/10.1111/jdv.20682","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.","authors":"Lian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, Inge Haeck, Celeste M Boesjes, Octavian I Bacoş-Cosma, Laura Loman, Marijke Kamsteeg, Simone Stadhouders-Keet, Albert J Oosting, Anneke M T van Lynden-van Nes, Klaziena Politiek, Antoni Gostynksi, Lisette Berntsen-Zandbergen, Wianda A Christoffers, Annebeth Flinterman, Wouter R H Touwslager, Berit Velstra, Shiarra M Stewart, Francine C van Erp, Marlies de Graaf, Marie-Louise A Schuttelaar, Marjolein S de Bruin-Weller","doi":"10.1111/jdv.20674","DOIUrl":"https://doi.org/10.1111/jdv.20674","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice.</p><p><strong>Objective: </strong>To assess the differential infection risk of biologic and JAKi treatment in patients with moderate-to-severe AD in a real-world setting.</p><p><strong>Methods: </strong>This prospective, multicentre study evaluated treatment-emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient-years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio-/JAKi-naïve patients.</p><p><strong>Results: </strong>In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4-65.5/100 PY) compared to biologics (13.6-22.0), especially for herpes infections (n = 195, 24.6%; JAKi 13.6-19.8 vs. biologicals 3.0-3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1-5.5; baricitinib HR 4.2, 95% CI: 2.9-6.2; upadacitinib HR 4.0, 95% CI: 3.2-5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0-2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4-2.6, p < 0.0001; 2.4, 1.3-4.4, p = 0.003, resp.), was identified as an independent factor associated with infection.</p><p><strong>Conclusion: </strong>This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate-to-severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient-specific risks such as prior skin infections.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining surgical margins for lentigo maligna with line-field confocal optical coherence tomography.","authors":"Juliette Archimbaud, Clothilde Raoux, Kevin Serror, Camille Gandon, Maxime Battistella, Céleste Lebbé, Barouyr Baroudjian","doi":"10.1111/jdv.20680","DOIUrl":"https://doi.org/10.1111/jdv.20680","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NLRP3 missense variant may contribute to dermatophytosis susceptibility.","authors":"Gabriela Blanchard, Maël Blanchard, Pacôme Prompsy, Marina Fratti, Ioannis Xenarios, Arkadiy Shevrikuko, Karine Salamin, Michel Monod, Emmanuella Guenova","doi":"10.1111/jdv.20658","DOIUrl":"https://doi.org/10.1111/jdv.20658","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YAP1-NUTM1 fusions are infrequent in porocarcinomas arising in a cohort including immunocompromised patients.","authors":"Mark Eisner, Remus Winn, Tom Oliphant, Miguel Joao Xavier, Akhtar Husain, Catherine A Harwood, Neil Rajan","doi":"10.1111/jdv.20681","DOIUrl":"https://doi.org/10.1111/jdv.20681","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing pigmented mucosal lesions: New insights from reflectance confocal microscopy","authors":"Mario Valenti,&nbsp;Francesco Piscazzi,&nbsp;Chiara Franceschini,&nbsp;Angela Ferrari,&nbsp;Pasquale Frascione,&nbsp;Marco Ardigò","doi":"10.1111/jdv.20656","DOIUrl":"10.1111/jdv.20656","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 7","pages":"e638-e641"},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the comment on Schneider et al. ‘Beyond the scoreboard (…)’","authors":"Sven Schneider,&nbsp;Zoe A. Parsons,&nbsp;Sophie Leer","doi":"10.1111/jdv.20677","DOIUrl":"10.1111/jdv.20677","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 8","pages":"e730-e731"},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.","authors":"Sophie L Preuß, Katja Bieber, Artem Vorobyev, Andreas Recke, Eva Lotta Moderegger, Henner Zirpel, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin, Ralf J Ludwig","doi":"10.1111/jdv.20670","DOIUrl":"https://doi.org/10.1111/jdv.20670","url":null,"abstract":"<p><strong>Background: </strong>Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.</p><p><strong>Objectives: </strong>To retrospectively assess the risk of APOs in dupilumab-treated pregnant women in a large real-world database.</p><p><strong>Methods: </strong>Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy-induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan-Meier method, outcome differences the log-rank test and hazard ratios (HR) the Cox regression model.</p><p><strong>Results: </strong>During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03-0.45, p = 0.0002) and 'any APO' (HR: 0.53, CI: 0.33-0.84, p = 0.0067) in the dupilumab-treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab-treated and untreated women up to 6 months before pregnancy or during the postpartum period.</p><p><strong>Conclusions: </strong>This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis’","authors":"","doi":"10.1111/jdv.20683","DOIUrl":"10.1111/jdv.20683","url":null,"abstract":"<p>De Greef A, Baeck M. Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. J Eur Acad Dermatol 2025;39(1):e94–e97. https://doi.org/10.1111/jdv.20132.</p><p>Regarding Patient #1, who was known to have classical severe atopic dermatitis since childhood, he had, like the other patients in the study, received a combination of a biologic and a JAK inhibitor, with an initial improvement consistent with the results presented in the article. However, he recently experienced yet another treatment failure, and a thorough investigation revealed a cutaneous T-cell lymphoma, likely related to the long-standing progression of his severe atopic dermatitis. Retrospectively, we realize that Figure 1 of the published article likely depicted the early signs of this lymphoma.</p><p>We apologize for this error.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20683","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}